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Abstract
Various E-ring hydroxylated antofine and cryptopleurine analogs were designed, synthesized, and
tested against five human cancer cell lines. Interesting structure-activity relationship (SAR)
correlations were found among these new compounds. The most potent compound 13b was
further tested against a series of non-small cell lung cancer (NSCLC) cell lines, in which it showed
impressive antiproliferative activity. Mechanistic studies revealed that 13b is able to down-
regulate HSP90 and β-catenin in A549 lung adenocarcinoma cells in a dose-dependent manner,
suggesting a potential use for treating Hedgehog pathway-driven tumorigenesis.
INTRODUCTION
Phenanthroindolizidine and phenanthroquinolizidine alkaloids, well-known for their
profound antiproliferative activity, are receiving renewed attention from scientists searching
for new cancer drugs with novel mechanism of action. These natural products, represented
by tylophorine, antofine, and cryptopleurine, have a common pentacyclic structure with the
phenanthrene ring conjugated with the indolizidine or quinolizidine moiety (Figure 1). Their
pharmacological use can be traced to ancient times when people used the leaves of these
plants to treat inflammation-related diseases, such as asthma, bronchitis, rheumatism, and
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dysentery.1 The NCI cancer drug screening program demonstrated that these natural
products generally exhibited significant activity with average IC50 values in the low nM
range.2 Other studies suggested that these molecules might act via several mechanisms,
possibly different from those of currently launched drugs.3 Many potential targets have been
reported, including inhibition of protein synthesis and ribosomal subunits,4 inhibition of
HIF-1,5 thymidylate synthase and dihydrofolate reductase,6 suppression of signaling
pathways such as NF-κB, AP-1, and CRE, as well as a number of cell cycle regulatory
proteins such as cyclin and cyclin dependent kinases.3
However, current research remains largely at bench-side due to the potential CNS toxicity of
tylophorine alkaloids, as observed with R-tylocrebine in early clinical trials. To circumvent
this problem, it was first proposed by Suffness in 1980 that increasing the polarity might
potentially reduce such side effects,7 but until now few efforts have been reported to address
this particular issue. A tylophorine analog with a C14 hydroxy group,
(13aS)-9,11,12,13,13a,14-hexahydro-2,3,6,7-tetramethoxy-dibenzo[f,h]pyrrolo[1,2-b]i
soquinolin-14-ol (DCB-3503), showed strong antiproliferative activity in vivo, possibly due
to an improved bioavailability profile.8 In addition, phenanthrene-based tylophorine analogs
exhibited strong antiproliferative activity both in vitro and in vivo without any notable toxic
effect in a xenograft mouse model of human lung tumor.9 Interestingly, our group recently
established a new synthetic methodology that is able to accommodate numerous E-ring
modified analogs from a key intermediate.10 We designed and synthesized a series of novel
analogs by incorporation of an extra heteroatom in the E-ring in order to increase the
polarity. Among the synthesized analogs, S-13-oxa-cryptopleurine and S-13-oxa-E7
exhibited antiproliferative activity in vitro with improved cancer cell line selectivity. In vivo
studies showed that the former compound was active against HT-29 human colorectal
adenocarcinoma xenograft in mice, in addition to exhibiting a desirable and expected ten-
fold reduction of toxicity against a primary human umbilical vein endothelial cell (HUVEC)
line when compared with R-cryptopleurine.11
Given the promise of our initial findings, we have further designed and synthesized a
number of novel E-ring modified compounds, in which a OH group has been introduced at
different positions of the E-ring of antofine (compounds 3a, 3b, 9a, and 9b) and
cryptopleurine (13a, 13b, 19a, 19b, 21a, and 21b). New E-ring dihydroxylated analogs (24a
and 24b) of R-cryptopleurine, along with other related analogs (25, 26a, and 26b), have also
been prepared and evaluated. These modifications allowed for an enhanced SAR analysis of
the effect of introducing polar functionalities. In this paper, we report the design, synthesis,
SAR, and mechanistic studies of hydroxylated antofine and cryptopleurine analogs as
promising anticancer agents, from which a refined structural design and optimization can be
rationalized.
CHEMISTRY
E-ring modifications of R-antofine
Compound 1 was prepared according to our published procedures. Following oxidation of
the hydroxymethyl group of 1 to an aldehyde, reaction with the enolate of EtOAc gave a pair
of diastereomers. Both intermediates underwent cyclization to afford an inseparable mixture
of 2a/b after removal of the Boc group. The resultant amides were reduced to give two C13
hydroxylated target products, 13S-hydroxy-S-antofine (3a) and 13R-hydroxy-S-
antofine(3b).
For the synthesis of C12-hydroxyl analogs, compound 4, obtained from compound 1 by
sequential oxidation and Wittig olefination, was condensed with 2-methoxyacrylic acid to
form amide 5 after deprotection. E-ring closure then took place through intramolecular ring-
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closure metathesis (RCM) using Grubb's catalyst to give compound 6. Following
regioselective reduction to give amine 7, acid-mediated cleavage of the enol ether furnished
ketone 8. The carbonyl group was reduced by NaBH4 to give the target product 12R-
hydroxy-S-antofine (9a) and 12S-hydroxy-S-antofine (9b) (Scheme 2).
E-ring modifications of R-cryptopleurine
For the three pairs of cryptopleurine analogs (13a/13b, 19a/19b, 21a/21b), the hydroxy
group was introduced at the C12, C13, and C14 position, respectively.
The known aldehyde 10 was reacted with vinylmagnesium bromide to give a mixture of
alcohols, which were oxidized to α,β-unsaturated ketone 11. The E-ring was then generated
through intramolecular Michael addition to give 12 after removal of the Boc group.
Subsequently the ketone was reduced using either NaBH4 to give 13a (13S-hydroxy-S-
cryptopleurine) and 13b-(13R-hydroxy-S-cryptopleurine) in a ratio of 3:7 or L-selectride
with a higher diastereomeric ratio (dr) of 1:9 (Scheme 3). Both compounds could also be
synthesized via a similar method as described in Scheme 1 starting from compound 10 in a
ratio of about 1:2.
The synthetic approach used to introduce the OH group at the C12 position is illustrated in
Scheme 4. Using this strategy, aldehyde 10 was reacted with Ph3P=CH2Br to produce
alkene 14, which was then coupled with 2-methoxyacrylic acid to give amide 15 after
removal of the Boc group. RCM furnished cyclized compound 16 and reduction produced
17. Hydrolysis of 17 gave the ketone 18, which was then reduced to alcohols 19a (12R-
hydroxy-R-cryptopleurine) and 19b (12S-hydroxy-R-cryptopleurine) with NaBH4 in a ratio
of 4:1. However, only 19a was isolated when L-selectride was used at a low temperature.
To achieve C14 hydroxylation, compound 1 was oxidized to an aldehyde followed by
nucleophilic addition of lithium propiolate prepared in situ. The intermediate alcohol
mixture was then hydrogenated, and subsequent cyclization afforded an inseparable mixture
of 20a/20b after deprotection. 1H-NMR indicated the two diastereomers were present in a
ratio of about 1:1. The target compounds 14S-hydroxy-S-cryptopleurine (21a) and 14R-
hydroxy-S-cryptopleurine (21b) were then obtained by borane dimethyl sulfide (BMS)
reduction (Scheme 5).
Besides E-ring monohydroxylation, other modifications included C12,13-dihydroxylation
(Scheme 6) and introduction of various other functionalities at the C13 position of
cryptopleurine (Scheme 7).
Compound 10 was converted to E)-alkene 22 using Ph3P=CH2CO2Et. Following
dihydroxylation, the intermediate was cyclized to give a mixture of 23a/23b after
deprotection. 1H-NMR indicated that the dr was about 5:4. The amide was then reduced to
afford 12S,13S-dihydroxy-S-cryptopleurine (24a) and 12R,13R-dihydroxy-S-cryptopleurine
(24b) using BMS.
For compound 25, ketone 12 was treated with EtMgBr, and only one diastereomer was
isolated. Because direct methylation of compound 13b failed to give 13-
methoxycryptopleurine 26, compounds 26a and 26b had to be prepared indirectly.
Compound 10 was subjected to nucleophilic addition with ethyl acetate using lithium
hexamethyldisilazide (LHMDS) followed by cyclization, as for conversion of 1 to 2a/2b.
The hydroxy group was then methylated using Me2SO4 and NaH, and the amide was
reduced by BMS to afford compounds 26a and 26b.
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The configurations of the new chiral center in compounds 3a/3b, 9a/9b, 13a/13b, 19a/19b,
21a/21b, 24a/24b, and 25 were determined from NOESY spectra. The configurations of 26a
and 26b were determined to be (13S,14aS) and (13R,14aS), respectively, by spectroscopic
correlation with compounds 13a and 13b (J = 2.8 Hz at C13).
RESULTS AND DISCUSSION
Selected new analogs were tested for antiproliferative activity against a panel of up to five
human cancer cell lines from diverse tissue sources, including A549 (lung), DU-145
(prostate), KB (nasopharyngeal), HCT-8 (colon), and SKBR3 (breast); KBvin is a type I
multi drug resistant (MDR-1) sub-line of KB that overexpresses P-glycoprotein. Blood-brain
penetration was predicted by PreADMET as reported previously.11
Regarding the C13-OH derivatives of R-antofine, both 3a and 3b showed decreased
antiproliferative activity (≥ 10 fold) in comparison with R-antofine. The 13R isomer 3b
exhibited three- to ten-fold higher activity than the 13S isomer 3a, indicating a favored
orientation of the OH group at this position. The C12 hydroxylated analogs (9a/9b) also
exhibited reduced activity at a level comparable with the C13 hydroxylated analogs;
however, it is still interesting to note that the 12R isomer 9a was about two- to three-fold
more active than its 12S isomer 9b. Although generally less active than the natural alkaloid,
these new compounds did demonstrate a conformational preference, likely due to increased
interaction with their potential targets. Intermediates 7 and 8 were also less active than
antofine. The IC50 values of compound 8 were similar to those of 9a, in the medium to high
nM range. These studies suggested that the C12 and C13 positions of R-antofine might not
be suitable for polar modifications, because the measured bioactivity was substantially
reduced, even though lowered BBB penetration was predicted.
In this study, we next examined structural optimization of cryptopleurine. The R-isomer has
shown comprehensive and superior antiproliferative activity with IC50 values as low as pM
range against all 60 cell lines in the NCI's screening program.2 With such profound
cytotoxicity, substantial activity could be retained even after introduction of polar elements.
Based on this line of reasoning, a hydroxy group was introduced at the C12, C13, or C14
position. The IC50 data of the mono-hydroxylated cryptopleurine analogs are listed in Table
2.
The results showed that 13a and 13b exhibited significant antiproliferative activity.
Compound 13b was at least two-fold more active than 13a with an average IC50 of 20 nM
against A549, DU145, KB, and KBvin. Compound 13b also exerted significant cytotoxic
activity against the SKBR3 breast cancer cell line with an IC50 of 72 nM, almost four-fold
more potent than 13a (IC50 of 295 nM). It is noteworthy that the ketone precursor 12 was
also active with an average IC50 less than 50 nM against four tested cancer cell lines; the
potencies, in general, fell between those of 13a and 13b. These data indicated that, for R-
cryptopleurine, the introduction of OH at C13 position is desirable as discussed above, and
therefore, this position may be amenable to further synthetic modification. When the
carbonyl group was moved to the C12 position as in compound 18, the activity was
substantially decreased by 15- to 30-fold in comparison with compound 12. This effect
might result from either a conformational mismatch with the putative targets or from the
reduced electron density on the N atom, because of the adjacent carbonyl in compound 18,
as it is well known that the C11 amide analogs of these natural products have negligible
activity. For 19a and 19b, the 12R-OH isomer showed considerably higher inhibition in
vitro (IC50 around 30–80 nM, except for SKBR3) than its 12S-OH isomer (IC50 > 2 μM).
The differences between C12-OH isomers were much higher and distinct than those
observed with C13-OH derivatives. Again, ketone 18 fell between the two C12-OH isomers
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with a potency order of 19a > 18 > 19b. The overall potency magnitudes showed that, for R-
cryptopleurine, the C13 position can more readily tolerate conformational changes, whereas
the C12 position is more intolerant of structural alterations, and the spatial orientation of the
OH group imposes more substantial effects on potency.
Investigation of C14 hydroxylation of R-cryptopleurine gave similar interesting results
(Table 2). The 14S-OH isomer 21a exhibited much greater activity than its 14R-OH isomer
21b (average IC50 values: 20 nM vs. 200 nM). Therefore, a similar preference for the OH
orientation was found with the hydroxylation at both C14 and C12 (the two positions β to
the N atom on the E-ring); namely, analogs with the C-O bond trans to the C14a-H bond
(19a, 21a) had much better antiproliferative activity than their cis counterparts (19b, 21b).
Among these four analogs, the rank order of potency was 21a (14S-OH) > 19a (12R-OH) >
21b (14R-OH) >> 19b (12S-OH). The data suggest that the OH group might exert smaller
steric and electronic differentiating effects at C14 relative to the C12 position. Therefore, the
C14 position was shown to be less demanding for modifications than the C12 position.
Furthermore, both 21a and 21b displayed moderate selectivity against the A549 cell line (10
and 69 nM), which R-cryptopleurine did not. All analogs showed remarkably reduced BBB
penetration compared with the parent compound as predicted by PreADMET.
Considering the interesting findings resulting from mono-hydroxylation, dihydroxylation at
C12 and C13 was investigated. The IC50 values are listed in Table 3. While both 24a and
24b exhibited low potency compared with the mono-hydroxylated analogs 13b and 19a,
compound 24a was significantly more potent than 24b. The latter result is in good
agreement with the SAR relationship established previously, as the two hydroxy groups in
24a are in the preferred orientations, i.e., those of 13b (13α OH) and 19a (12β OH).
However, the activity loss could be either target-dependent or possibly related to cell
permeability.
Geminal substituents (Et and OH) or a methoxy group were also introduced at the C13
position of R-cryptopleurine, and the resulting compounds were tested in vitro. The IC50
data are shown in Table 4. The antiproliferative activity of analog 13b was compromised by
the introduction of an ethyl group at C13 (25 exhibited about 40-fold lower activity), which
might be caused by steric factors. The effect of introducing a methoxy group at C13 was
very interesting, as the two diastereomers 26a and 26b showed distinct cell growth
inhibition profiles. The 13R-OMe isomer 26b exhibited significant cytotoxicity (average
IC50 < 100 nM), while the 13S-OMe isomer 26a showed a substantial decrease in efficacy
(average IC50 > 3 μM). Interestingly, this disparity was not observed between 13a and 13b,
the corresponding hydroxy analogs of 26a and 26b, respectively. In addition, the fact that
26b was about two-fold less active than 13b, suggested that group bulkiness or a hydrogen
bonding effect may potentially be involved. Overall, the SAR analysis around the C13
position showed that polar substituents syn to the C14a-H are favorable for maintaining the
high cytoxicity of R-cryptopleurine, and OMe versus OH results in decreased potency, but
greater stereochemical preference.
In summary, several polar R-cryptopleurine analogs, 12, 13a, 13b, 19a, 21a, and 26b that
retain significant antiproliferative activity were developed, and new and important SAR
information was obtained for each position examined. Because the preliminary cytotoxicity
profile indicated some specificity towards the lung cancer cell line A549, selected
compounds were evaluated for cytotoxic effect against CL1-5 NSCLC cells through an SRB
assay. The results shown in Figure 2 demonstrated that (after the cells were treated with
increasing concentration for 48 h), compound 13b was the most potent inhibitor against
CL1-5 cell growth, showing significant cytotoxicity consistent with the earlier study in
A549 cells. To explore the effects of 13b on other NSCLC cells in addition to CL1-5, follow
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up assays using CL1-0, PC9, and PC9IR cell lines were conducted, and the cytotoxicity
results are shown in Table 5. Compound 13b strongly inhibited replication of all cell lines,
with highest activities against CL1-5, PC9 (~ 8 nM), and A549 (9 nM), while R-
cryptopleurine showed a uniform higher potency in the same assay. It is exciting and
interesting to note that, as compared with cryptopleurine (IC50 ~ 14 nM), analog 13b with a
13R hydroxy group exhibited lowered toxicity (IC50 ~ 100 nM) against normal human lung
fibroblasts, MRC-5, and thus, improved selectivity in this study, (Table 5), while another
published analog, S-13-oxa-cryptopleurine, exhibited even lower toxicity (IC50 ~ 250 nM)
against MRC-5 cells. These results demonstrated that our structural modification strategy,
namely, the introduction of polar functionalities on the E-ring to reduce potential side effects
of this family of natural alkaloids, holds great promise. Compound 13b was subsequently
selected for further molecular cell-based functional study. A549 cells were treated with
increasing concentrations of 13b for 48 h, and morphological observations were captured by
using an inverted phase-contrast microscope and photographed. As shown in Figure 3, the
number of A549 cells, but not the morphology, was markedly decreased upon treatment with
13b at 60 nM, suggesting that 13b significantly inhibits NSCLC proliferation through a
mechanism other than morphological effects.
In order to understand the molecular mechanism of 13b-induced cytotoxicity, a gene
expression analysis (MetaCore database) was performed using the A549 cancer cell line.
Up- or down-regulated genes in 13b-treated A549 cells (expression level was 10-fold
greater or lower than untreated cells) are summarized in Table 6. Although the microarray
used in the current study contained a limited number of genes, we found that genes involved
in the Hedgehog signaling pathway exhibited high statistically significant differences (Table
6 and Figure 3), including up-regulation of ubiquitin, and down-regulation of heat shock
protein 90 (HSP90) and β-catenin. As many HSP client proteins, such as β-catenin, are
known to play critical roles in human cancers, and strategies targeting HSP have been
developed for therapeutic applications in human cancers, we focused in particular on the
down-regulation of HSP90 and β-catenin in 13b-treated A549 cells. RT-PCR (Figure 4a)
confirmed that both proteins were remarkably decreased after exposure to 13b (3.6 nM) for
48 h. To further evaluate the significance of these findings, the protein levels of HSP90, p-
GSK3β, β-catenin, and β-catenin downstream target genes, such as cyclin D, were
determined by Western blot analysis, using R-cryptopleurine as a comparison. Similar
inhibition patterns were observed with 13b showing stronger suppression of HSP90 and β-
catenin than R-cryptopleurine, as opposed to cyclin D (Figure 4b). These findings suggest
that 13b down-regulates HSP90 and β-catenin, which might lead to down-regulation of
cyclin D (a common key effector) as proposed in Figure 5. However, it should not be ruled
out that the reduction of other RNAs and associated protein levels, if any, might also
contribute to the observed potent cytotoxicity of cryptopleurine and related analogs
described herein. Several lines of evidence indicate functional interactions between two
critical pathways, SHH (sonic hedgehog) and Wnt/β-catenin. It has been recently reported
that Wnt/β-catenin signaling is required for Hedgehog pathway-driven tumorigenesis.12
Therefore, it might be very important to block Wnt signaling, given its activation in
NSCLCs. In addition, HSP90, the signal transduction chaperone, maintains intracellular
communication in normal, stem, and cancer cells. The well-characterized associations of
HSP90 with its client kinases form the framework of multiple signaling networks. Recently,
HSP90 has emerged as a target of interest in cancer therapy. Moreover, evidence also
suggests that the β-catenin/TCF7L2 pathway plays an important role in HSP90 inhibitor-
induced cell death in ATL cells (adult T-cell leukemia) and HTLV-1 (human T-cell
leukemia virus type 1) transformed cells,13 and HSP90 co-localizes with GSK3β and β-
catenin in the human MCF-7 epithelial breast cancer model. These data indicate that β-
catenin could be considered as a novel HSP90 client protein. However, the proposed
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mechanism in Figure 5 still needs further direct evidence, as some of the gene expressions
were validated only at RNA levels, which do not necessarily translate into protein levels. In
addition, the degree of HSP90 involvement in Wnt/β-catenin signaling and the role of 13b in
the complex merit further investigation.
CONCLUSION
In this paper, we designed and synthesized novel polar antofine and cryptopleurine analogs.
Several analogs exhibited significant inhibition of cancer cell growth in vitro, and a detailed
SAR discussion was provided. The higher polarity of these new analogs could potentially
reduce CNS toxicity, a major drawback of the natural phenanthroindolizidines and
phenanthroquinolizidines. Mechanistic studies suggested that these new analogs interact
with the Hedgehog signaling pathway to exert their profound cytotoxicity, probably by
inhibiting HPS90 or β-catenin activity, as demonstrated by cDNA microarray analysis.
Therefore, these compounds could potentially be useful in treating HSP90- or β-catenin-
related carcinogenesis. Similar structural modifications are being studied with another
member of this alkaloid family, tylophorine. Additional mechanistic studies are still
underway, and the results will be reported in due course.
EXPERIMENTAL SECTION
All chemicals were used as purchased. Melting points were measured using a Fisher Johns
melting apparatus without correction. Proton nuclear magnetic resonance (1H NMR) spectra
were measured on a 300 MHz Gemini or a Varian Inova (400 MHz) NMR spectrometer
with TMS as the internal standard. The solvent used was CDCl3 unless otherwise indicated.
Mass spectra were recorded on a Shimazu-2010 LC/MS/MS instrument equipped with a
TurboIonsSpray ion source. All final target compounds were characterized and determined
as at least >95% pure by analytical HPLC.
(13R/S,13aS)-11-Oxo-13-hydroxyantofine (2a/2b)
Alcohol 1 (113 mg, 0.25 mmol) was dissolved in CH2Cl2 (10 mL) and Et3N (0.14 mL, 1
mmol), to which sulfur trioxide pyridine complex (Py•SO3) (120 mg, 0.75 mmol) in DMSO
was added dropwise. The mixture was stirred for 1.5 h, and then 1N HCl was added. The
organic layer was washed with sat. NaHCO3 and brine, and dried over MgSO4. In another
flask, ethyl acetate (30 μL, 0.30 mmol) was added to lithium bis(trimethylsilyl)amide
(LiHMDS) (0.33 mmol) in THF at −78 °C with stirring for 1h, and the aldehyde from the
first reaction was added slowly in THF. The mixture was stirred for 3 h until TLC indicated
complete disappearance of the aldehyde. Sat. NH4Cl was added to quench the reaction, and
most of the solvent was removed in vacuo. CH2Cl2 was added and the organic layer was
washed with sat. NaHCO3 and brine, and dried over Na2SO4. After evaporation of solvent,
the residue was dissolved in TFA/CH2Cl2, and stirred for 1 h. After removal of TFA in
vacuo, Et3N (0.20 mL) and MeOH (10 mL) were added. The mixture was refluxed for 1 h.
Chromatography using CH2Cl2/MeOH gave 56 mg (57% over four steps) of an inseparable
mixture of 2a/2b in a ratio of 2:1 as a white solid. 1H NMR (400 MHz, CDCl3): δ 7.87 (s,
1H), 7.85 (d, J = 2.4 Hz, 1H), 7.80 (d, J = 9.2 Hz, 1H), 7.63 (s, 0.5H), 7.54 (d, J = 2.4 Hz,
0.52H), 7.31 (d, J = 8.8 Hz, 0.55 H), 7.22–7.19 (m, 2H), 7.15 (s, 0.51H), 6.76 (dd, J = 9.2
Hz, J = 2.4 Hz, 0.52H), 5.38 (d, J = 17.2 Hz, 1H), 4.93 (d, J = 17.6 Hz, 0.56 H), 4.66 (m,
0.58 H), 4.57 (d, J = 17.2 Hz, 1H), 4.51 (m, 1H), 4.40 (d, J = 17.6 Hz, 0.59H), 4.11 (s,
4.23H), 4.04 (s, 4.25H), 4.01 (s, 2.79H), 3.90 (s, 1.49H), 3.85–3.75 (m, 1.69 H), 3.51 (dd, J
= 15.6 Hz, J = 4.0 Hz, 1H), 3.40 (dd, J = 16.0 Hz, J = 11.2 Hz, 0.64H), 3.18–3.09 (m,
1.24H), 2.94 (dd, J = 17.6 Hz, J = 7.2 Hz, 1H), 2.88 (dd, J = 6.4 Hz, J = 17.6 Hz, 0.50H),
2.74 (dd, J = 15.2 Hz, J = 11.2 Hz, 1H), 2.66 (d, J = 18.0 Hz, 0.60H), 2.59 (dd, J = 17.6 Hz,
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J = 2.4 Hz, 1H); ESI MS m/z 394.10 (M+H)+. ESI-HRMS ([M + H]+) calcd for C23H23NO5
394.1654, found 394.1660.
(13S,13aS)-13-Hydroxyantofine (3a) and (13R,13aS)-13-hydroxyantofine (3b)
Compound 2a/2b (56 mg) was suspended in THF and LiAlH4 (20 mg, 0.50 mmol) was
added. The mixture was stirred at rt for 1 h. Water and 1N NaOH were then added and the
mixture was filtered. CH2Cl2 was used for extraction in a normal workup. Chromatography
using CH2Cl2/MeOH gave 27 mg of 3a (48%) and 12 mg (22%) of 3b as white solids. For
3a: mp 170–172 °C; [α]23D= −7.3 ° (c 0.83, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.88
(d, J = 2.8 Hz, 1H), 7.79 (s, 1H), 7.76 (d, J = 9.2 Hz, 1H), 7.17 (dd, J = 9.2 Hz, J = 2.4 Hz,
1H), 6.77 (s, 1H), 4.67 (d, J = 14.8 Hz, 1H), 4.32 (m, 1H), 4.10 (s, 3H), 4.02 (s, 3H), 3.66 (s,
3H), 3.58 (d, J = 15.2 Hz, 1H), 3.51 (dt, J = 8.8 Hz, J = 2.4 Hz, 1H), 3.11 (dd, J = 16.0 Hz, J
= 11.2 Hz, 1H), 2.93 (dd, J = 16.0 Hz, J = 3.2 Hz, 1H), 2.46–2.40 (m, 1H), 2.36–2.26 (m,
2H), 1.93–1.88 (m, 1H); ESI-HRMS ([M + H]+) calcd for C23H25NO4 380.1862, found
380.1858. For 3b: mp 182–184 °C; [α]23D= −92.2 ° (c 0.18, CHCl3); 1H NMR (400 MHz,
CDCl3): δ 7.88–7.87 (m, 2H), 7.77 (d, J = 9.2 Hz, 1H), 7.29 (s, 1H), 7.19 (dd, J = 9.2 Hz, J
= 2.4 Hz, 1H), 4.58 (d, J = 15.2 Hz, 1H), 4.35–4.30 (m, 1H), 4.09 (s, 3H), 4.04 (s, 3H), 4.01
(s, 3H), 3.74 (d, J = 14.8 Hz, 1H), 3.47 (dd, J = 15.6 Hz, J = 2.8 Hz, 1H), 3.37 (dt, J = 8.8
Hz, J = 2.4 Hz, 1H), 2.96 (dd, J = 15.2 Hz, J = 11.2 Hz, 1H), 2.72 (q, J = 9.2 Hz, 1H), 2.50–




Compound 4 (900 mg, 2 mmol) was dissolved in TFA/CH2Cl2 (20 mL) at rt, and the
mixture was stirred for 1 h. The solvent was removed by evaporation and TFA was
neutralized with N-methylmorpholine (NMM). The residue was redissolved in DMF (20
mL), to which 2-methoxyacrylic acid (224 mg, 2.20 mmol), 1-ethyl-3-(3-
dimethyllaminopropyl)carbodiimide hydrochloride (EDC•HCl) (478 mg, 2.50 mmol),
hydroxybenzotriazole (HOBt) (340 mg, 2.50 mmol), and NMM (0.80 mL) were added.
Stirring was continued overnight. DMF was then removed under reduced pressure, and the
residue was dissolved in CH2Cl2 (50 mL), washed with HCl (1N), sat. NaHCO3, and brine,
and dried over MgSO4. Compound 5 (727 mg, 83% in two steps) was isolated by column
chromatography eluting with EtOAc/hexane. mp 74–76 °C; [α]23D= 71.5 ° (c 1.16,
CHCl3); 1H NMR (400 MHz, CDCl3, compound rotameric at rt): δ 7.89–7.84 (m, 3H), 7.28
(s, 1H), 7.21 (dd, J = 9.2 Hz, J = 2.8 Hz, 1H), 5.88–5.61 (m, 2H), 5.20–5.10 (m, 3H), 4.64
(d, J = 3.2 Hz, 1H), 4.54 (m, 1H), 4.46 (d, J = 3.2 Hz), 4.09 (s, 3H), 4.05 (s, 3H), 4.00 (s,
3H), 3.73 (s, 3H), 3.43–3.28 (m, 2H); 13C NMR (100 MHz, CDCl3): δ 165.9, 162.6, 157.9,
157.2, 149.7, 148.8, 135.9, 130.4, 126.5, 124.3, 123.8, 123.7, 123.3, 117.7, 115.2, 105.0,
104.1, 103.9, 56.1, 56.0, 55.6, 55.3, 53.8, 39.6, 36.5, 31.5, 30.3; ESI-HRMS ([M + H]+)
calcd for C26H27NO5 434.1967, found 434.1963.
(S)-11-Oxo-12-methoxy-antofine-12-ene (6)
Compound 5 (727mg, 1.66 mmol) was dissolved in anhydrous CH2Cl2 under N2, to which
Grubb's 2nd generation catalyst in CH2Cl2 was added in one portion. The reaction was
stirred at reflux for 2 h or monitored by TLC. Compound 6 (596 mg) was isolated by
column chromatography eluting with CH2Cl2/MeOH as a light yellow solid. Yield: 88%. mp
135–137 °C; [α]23D= −235 ° (c 1.11, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.80 (s, 1H),
7.79 (d, J = 2.8 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.20–7.17 (m, 2H), 6.00 (d, J = 2.4 Hz,
1H), 5.37 (d, J = 17.6 Hz, 1H), 4.65 (d, J = 17.2 Hz, 1H), 4.16–4.12 (m, 1H), 4.10 (s, 3H),
4.03 (s, 3H), 4.00 (s, 3H), 3.86 (s, 3H), 3.52 (dd, J = 11.6 Hz, J = 4.8 Hz, 1H), 2.53 (dd, J =
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15.6 Hz, J = 11.6 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ 163.9, 158.0, 153.1, 149.5,
148.7, 130.4, 126.0, 124.1, 124.0, 123.2, 123.2, 122.4, 115.3, 108.7, 104.9, 104.0, 103.9,
57.5, 56.1, 56.0, 55.6, 52.4, 40.4, 31.4; ESI-HRMS ([M + H]+) calcd for C24H23NO5
406.1654, found 406.1667.
(S)-12-Methoxyantofine-12-ene (7)
The amide 6 (450 mg, 1.11 mmol) and LiAlH4 (2 equiv.) were suspended in THF (15 mL),
which was stirred for 2 h. Water was then added to quench the reaction, followed by aq.
NaOH (1N, 1 mL) and H2O (1 mL). The mixture was filtered and then extracted with CHCl3
and dried over MgSO4. Column chromatography eluting with CH2Cl2/MeOH gave the
target product 7 (300 mg) as a light yellow solid. Yield: 69%. mp 202–204 °C; [α]23D= 97.0
° (c 0.47, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.91 (s, 1H), 7.90 (d, J = 2.4 Hz, 1H),
7.80 (d, J = 8.8 Hz, 1H), 7.33 (s, 1H), 7.20 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 4.83 (s, 1H),
4.52 (d, J = 14.4 Hz, 1H), 4.10 (s, 3H), 4.06 (s, 3H), 4.05 (d, J = 14.4 Hz, 1H), 4.01 (s, 3H),
3.83 (d, J = 7.2 Hz, 1H), 3.72 (s, 3H), 3.58 (m, 2H), 3.32 (d, J = 15.2 Hz, 1H), 3.02 (m,
1H); 13C NMR (100 MHz, CDCl3): δ 159.7, 157.7, 149.6, 148.6, 130.2, 127.7, 127.6, 125.8,
124.5, 124.4, 123.7, 115.1, 104.8, 104.3, 104.0, 95.3, 63.7, 57.8, 57.0, 56.2, 56.0, 55.7, 51.8,
33.8; ESI-HRMS ([M + H]+) calcd for C24H25NO4 392.1862, found 392.1865.
(S)-12-Oxo-antofine (8)
Compound 7 (300 mg) was refluxed in HCl/THF for 2 h before the solvent was evaporated.
NaOH was used for neutralization and CH2Cl2 used for extraction. Chromatography gave
200 mg of compound 8 as a light yellow solid (68%). mp 240–242 °C; [α]23D= −34.7 ° (c
0.91, CHCl3); IR (FT-IR ATR, cm−1) 2833, 1751, 1609, 1510, 1260, 1234, 1208, 1202,
1126, 867, 777; 1H NMR (400 MHz, CDCl3): δ 7.92 (s, 1H), 7.91 (d, J = 2.4 Hz, 1H), 7.78
(d, J = 8.8 Hz, 1H), 7.27 (s, 1H), 7.22 (dd, J = 9.2 Hz, J = 2.6 Hz, 1H), 4.70 (d, J = 14.8 Hz,
1H), 4.11 (s, 3H), 4.06 (s, 3H), 4.02 (s, 3H), 3.84 (d, J = 15.2 Hz, 1H), 3.78 (d, J = 16.8 Hz,
1H), 3.43 (d, J = 13.2 Hz, 1H), 3.07–3.01 (m, 2H), 2.98 (d, J = 16.4 Hz, 1H), 2.76 (dd, J =
17.6 Hz, J = 5.2 Hz, 1H), 2.43 (dd, J = 17.6 Hz, J = 10.0 Hz, 1H); 13C NMR (100 MHz,
CDCl3): δ 212.4, 157.7, 149.5, 148.6, 130.2, 126.6, 125.7, 124.5, 124.0, 123.7, 123.6, 115.1,
104.7, 103.8, 103.7, 63.1, 57.9, 56.0, 55.9, 53.4, 44.7, 33.2; ESI-HRMS ([M + H]+) calcd for
C23H23NO4 378.1705, found 378.1704.
(12R,13aS)-12-Hydroxyantofine (9a) and (12S,13aS)-12-hydroxyantofine (9b)
The ketone 8 (38 mg, 0.10 mmol) was suspended in MeOH, to which NaBH4 (19 mg, 0.50
mmol) was added at r.t. The mixture was stirred for 1 h before sat. NaHCO3 was added.
After normal workup, chromatography using MeOH/CH2Cl2 gave 19 mg of 9a (50%) and
12 mg of 9b (31%) as white solids. For 9a: mp 235 °C (dec.); [α]23D= −104.5 ° (c 0.20,
CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.85 (s, 2H), 7.69 (d, J = 9.2 Hz, 1H), 7.18 (s, 1H),
7.12 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 4.57 (d, J = 14.8 Hz, 1H), 4.41 (m, 1H), 4.09 (s, 3H),
3.99 (s, 6H), 3.57 (d, J = 14.8 Hz, 1H), 3.33 (d, J = 10.4 Hz, 1H), 3.26 (dd, J = 15.6 Hz, J =
2.8 Hz, 1H), 2.88 (dd, J = 15.2 Hz, J = 10.8 Hz, 1H), 2.75–2.68 (m, 1H), 2.54–2.50 (m, 1H),
2.42–2.38 (m, 1H), 1.74–1.68 (m, 1H); ESI-HRMS ([M + H]+) calcd for C23H25NO4
380.1862, found 380.1866. For 9b: mp 250 °C (dec.); [α]23D= 19.5 ° (c 0.12, CHCl3); 1H
NMR (400 MHz, CDCl3): δ 7.92 (s, 1H), 7.90 (d, J = 2.4 Hz, 1H), 7.80 (d, J = 9.2 Hz, 1H),
7.30 (s, 1H), 7.21 (dd, J = 9.2 Hz, J = 2.8 Hz, 1H), 4.65 (m, 1H), 4.63 (d, J = 14.8 Hz, 1H),
4.11 (s, 3H), 4.06 (s, 3H), 4.02 (s, 3H), 3.86–3.80 (m, 2H), 3.41 (m, 1H), 3.35 (d, J = 14.8
Hz, 1H), 2.95–2.83 (m, 2H), 2.49 (dd, J = 10.0 Hz, J = 4.8 Hz, 1H), 2.20–2.05 (m, 2H); ESI-
HRMS ([M + H]+) calcd for C23H25NO4 380.1862, found 380.1861.
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Compound 10 (700 mg, 1.50 mmol) was dissolved in THF (20 mL), to which
vinylmagnesium bromide (3.50 mL, 3.50 mmol) was added dropwise at 0 °C. After 2 h of
stirring, sat. NH4Cl was added to quench the reaction and the mixture was extracted with
CH2Cl2. The organic layer was washed with aq. NaHCO3 and brine. After drying over
Na2SO4, the mixture was evaporated and the residue was redissolved in anhydrous CH2Cl2.
Dess-Martine periodinane (848 mg, 2 mmol) was added and the reaction mixture was stirred
for 4 h. Na2S2O3 (500 mg) was added followed by sat. NaHCO3, and the mixture was stirred
for 10 min. The mixture was extracted with CH2Cl2 and the organic layers were combined,
washed with brine, and dried over MgSO4. The solvent was removed and the crude was
chromatographed using EtOAc/hexane to give 11 (434 mg, 57%) as a light yellow foam. mp
156–158 °C; [α]23D= 111.8 ° (c 0.11, CHCl3); 1H NMR (400 MHz, CDCl3, peak broadened
due to rotamers at r.t.): δ 7.87 (brs, 3H), 7.22 (brs, 2H), 6.30 (dd, J = 17.2 Hz, J = 10.4 Hz,
1H), 6.13 (d, J = 17.6 Hz, 1H), 5.77 (d, J = 6.8 Hz, 1H), 5.27 (m, 2H), 4.61 (m, 1H), 4.08 (s,
3H), 4.02 (s, 3H), 4.00 (s, 3H), 3.32 (dd, J = 16.4 Hz, J = 6.0 Hz, 1H), 3.15 (brs, 1H), 2.85–
2.75 (m, 2H), 1.53 (s, 9H); ESI-HRMS ([M + H]+) calcd for C29H33NO6 492.2386, found
492.2372.
(S)-13-Oxo-cryptopleurine (12)
To a solution of compound 11 (245 mg, 0.50 mmol)in CH3CN (50 ml) at 0 °C was added
TMSI dropwise (3 equiv.). The mixture was stirred for 15 min before the solvent was
removed. Then the residue was dissolved in CH2Cl2 (5 mL) and MeOH (20 mL), to which
Cs2CO3 (326 mg, 1 mmol) was added in one portion. The mixture was refluxed overnight.
After evaporation of the solvent, the crude product was chromatographed using CH2Cl2/
MeOH to afford 12 (123 mg, 63%) as a light yellow solid. mp 113–115 °C; [α]23D= 103.9 °
(c 0.12, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.81–7.80 (m, 2H), 7.68 (d, J = 9.2 Hz,
1H), 7.16 (dd, J = 8.8 Hz, J = 2.4 Hz, 1H), 7.04 (s, 1H), 4.42 (d, J = 15.6 Hz, 1H), 4.06 (s,
3H), 4.00 (s, 3H), 3.98 (s, 3H), 3.54 (dd, J = 15.6 Hz, 1H), 3.43–3.38 (m, 1H), 2.87 (dd, J =
16.0 Hz, J = 3.2 Hz, 1H), 2.81–2.73 (m, 2H), 2.61–2.40 (m, 5H); ESI-HRMS ([M + H]+)
calcd for C24H25NO4 392.1862, found 392.1856.
(13S,14aS)-13-Hydroxycryptopleurine (13a) and (13R,14aS)-13-hydroxycryptopleurine (13b)
To a solution of compound 12 (39 mg, 0.10 mmol) in MeOH was added NaBH4 (19 mg,
0.50 mmol). The reaction mixture was stirred for 2 h before sat. NaHCO3 was added. The
mixture was then extracted using CH2Cl2 and the organic layers were washed with brine and
dried over Na2SO4. The crude product was chromatographed using MeOH/CH2Cl2 to give
13a (9 mg, 24%) and 13b as white solids (21 mg, 55%). The diastereoselectivity was further
increased using L-selectride in THF at −78 °C to give 13a/13b in a ratio of 1/9. For 13a: mp
222 °C (dec.); [α]23D= −95.4 ° (c 0.11, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.89–7.88
(m, 2H), 7.75 (d, J = 9.0 Hz, 1H), 7.34 (s, 1H), 7.20 (dd, J = 9.0 Hz, J = 2.1 Hz, 1H), 4.43 (d,
J = 15.6 Hz, 1H), 4.07 (s, 3H), 4.04 (s, 3H), 3.99 (s, 3H), 3.69 (m, 1H), 3.54 (d, J = 15.6 Hz,
1H), 3.26 (m, 1H), 3.02 (m, 1H), 2.89 (m, 1H), 2.42–2.59 (m, 3H), 2.07 (m, 1H), 1.72 (m,
1H); ESI-HRMS ([M + H]+) calcd for C24H27NO4 394.2018, found 394.2020. For 13b: mp
230 °C (dec.); [α]23D= −144.7 ° (c 0.10, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.90 (s,
1H), 7.89 (d, J = 2.7 Hz, 1H), 7.80 (d, J = 9.0 Hz, 1H), 7.23 (s, 1H), 7.19 (dd, J = 9.0 Hz, J =
2.4 Hz, 1H), 4.46 (d, J = 15.6 Hz, 1H), 4.29 (m, 1H), 4.10 (s, 3H), 4.05 (s, 3H), 4.01 (s, 3H),
3.72 (d, J = 15.3 Hz, 1H), 3.08–3.04 (m, 2H), 2.86–2.72 (m, 2H), 2.15–2.03 (m, 2H), 1.90–
1.74 (m, 2H); ESI-HRMS ([M + H]+) calcd for C24H27NO4 394.2018, found 394.2019.
Yang et al. Page 10














To a solution of Ph3P=CH2Br (1.43 g, 4 mmol) in THF was added n-BuLi (2M in heptanes,
1.95 mL) at 0 °C under N2. The mixture was stirred for 0.5 h before compound 8 (970 mg,
2.08 mmol) in THF (10 mL) was added dropwise. The mixture was then stirred for 2 h
(monitored by TLC). Sat. NH4Cl was added to quench the reaction and THF was removed
by evaporation. The residue was dissolved in CH2Cl2, washed with sat. NaHCO3 and brine,
and dried over MgSO4. Column chromatography eluting with EtOAc/hexane gave 9 (820
mg, 85%) as a light yellow foam. mp 87–89 °C; [α]23D= 132.7 ° (c 0.15, CHCl3); 1H NMR
(400 MHz, CDCl3, peak broadened due to rotamers at r.t.): δ 7.92–7.87 (m, 3H), 7.277.23
(m, 2H), 5.89–5.83 (m, 1H), 5.34 (brs, 1H), 5.05–4.79 (m, 3H), 4.53 (d, J = 17.2 Hz, 1H),
4.11 (s, 3H), 4.04 (s, 3H), 4.02 (s, 3H), 3.26 (dd, J = 16.0 Hz, J = 2.0 Hz, 1H), 3.10 (d, J =
16.4 Hz, 1H), 2.41–2.33 (m, 1H), 2.21–2.18 (m, 1H), 1.54 (s, 9H); ESI-HRMS ([M + H]+)
calcd for C28H33NO5 464.2437, found 464.2440.
(S)-N-2'-Methoxypropenoyl-6,7,10-trimethoxy-3-(3'-propenyl)-1,3,4-trihydrodib e-nzo[f,h]-
isoquinoline (15)
Similar procedure as for compound 5. Yield: 77% over two steps. mp 84–86 °C; [α]23D=
104.9 ° (c 4.30, CHCl3); 1H NMR (400 MHz, CDCl3, peak broadened due to rotamers at
r.t.): δ 7.93–7.70 (m, 3H), 7.25–7.22 (m, 2H), 5.84–5.76 (m, 1H), 5.68 (d, J = 18.0 Hz, 1H),
5.34–5.16 (m, 0.65H), 5.07 (d, J = 10.4 Hz, 1H), 5.01 (d, J = 17.2 Hz, 1H), 4.77 (d, J = 16.8
Hz, 0.29H), 4.61–4.40 (m, 3H), 4.10 (s, 3H), 4.04 (s, 3H), 4.01 (s, 3H), 3.31 (dd, J = 16.0
Hz, J = 4.8 Hz, 1H), 3.14 (d, J = 15.6 Hz, 1H), 2.48–2.41 (m, 1H), 2.29–2.25 (m, 1H); ESI-
HRMS ([M + H]+) calcd for C27H29NO5 448.2124, found 448.2121.
(R)-11-Oxo-12-methoxycryptopleurine-12-ene (16)
Similar procedure as for compound 6. Yield: 65%. mp 276–278 °C; [α]23D= 246.0 ° (c 0.16,
CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.89 (d, J = 8.8 Hz, 1H), 7.85 (s, 1H), 7.84 (d, J =
2.4 Hz, 1H), 7.22 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 7.16 (s, 1H), 5.73 (d, J = 17.2 Hz, 1H),
5.38 (t, J = 4.8 Hz, 1H), 4.62 (d, J = 17.2 Hz, 1H), 4.16–4.12 (m, 1H), 4.08 (s, 3H), 4.03 (s,
3H), 4.00 (s, 3H), 3.95–3.90 (m, 1H), 3.66 (s, 3H), 3.24 (dd, J = 16.0 Hz, J = 11.6 Hz, 1H),
3.00 (dd, J = 16.0 Hz, J = 2.8 Hz, 1H), 2.94 (ddd, J = 17.2 Hz, J = 8.0 Hz, J = 4.0 Hz, 1H),
2.52 (dt, J = 17.2 Hz, J = 5.2 Hz, 1H); ESI-HRMS ([M + H]+) calcd for C25H25NO5
420.1811, found 420.1826.
(R)-12-Methoxycryptopleurine-12-ene (17)
Similar procedure as for compound 7. Yield: 70%. mp 213–215 °C; [α]23D= 17.3 ° (c 0.10,
CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.90 (s, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.79 (d, J =
9.2 Hz, 1H), 7.26 (s, 1H), 7.19 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 4.71 (m, 1H), 4.47 (d, J =
16.0 Hz, 1H), 4.10 (s, 3H), 4.06 (d, J = 16.0 Hz, 1H), 4.05 (s, 3H), 4.00 (s, 3H), 3.58 (s, 3H),
3.44 (d, J = 16.0 Hz, 1H), 3.28 (dd, J = 15.6 Hz, J = 1.6 Hz, 1H), 3.21–3.14 (m, 2H), 3.00–
2.94 (m, 1H), 2.49–2.45 (m, 1H), 2.33–2.27 (m, 1H); ESI-HRMS ([M + H]+) calcd for
C25H27NO4 406.2018, found 406.2030.
(R)-12-Oxo-cryptopleurine (18)
Similar procedure as for compound 8. Yield: 80%. mp 96–98 °C; [α]23D= 82.4 ° (c 0.15,
CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.90 (s, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.73 (d, J =
9.2 Hz, 1H), 7.22 (s, 1H), 7.19 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 4.38 (d, J = 15.6 Hz, 1H),
4.10 (s, 3H), 4.05 (s, 3H), 4.01 (s, 3H), 3.75 (d, J = 15.6 Hz, 1H), 3.63 (dd, J = 14.8 Hz, J =
1.2 Hz, 1H), 3.19 (dd, J = 16.0 Hz, J = 2.4 Hz, 1H), 3.10 (d, J = 14.8 Hz, 1H), 2.93 (dd, J =
16.0 Hz, J = 10.0 Hz, 1H), 2.87–2.82 (m, 1H), 2.68–2.63 (m, 1H), 2.52–2.44 (m, 1H), 2.36–
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2.29 (m, 1H), 2.00–1.91 (m, 1H); ESI-HRMS ([M + H]+) calcd for C24H25NO4 392.1862,
found 392.1859.
(12R,14aR)-12-Hydroxy-cryptopleurine (19a) and (12S,14aR)-12-hydroxy--cryptopleurine
(19b)
The ketone 18 (39 mg, 0.10 mmol) was suspended in MeOH, to which NaBH4 (19 mg, 0.50
mmol) was added at rt. The mixture was stirred for 1 h before sat. NaHCO3 was added.
After normal workup, chromatography using MeOH/CH2Cl2 gave 23 mg of 19a (58%) and
6 mg of 9b (15%) as white solids. The reaction was also performed with L-selectride at 0 °C
and only 19a was isolated (31 mg, 80%). For 19a: mp 206 °C (dec.); [α]23D= −61.0 ° (c
0.13, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.89 (s, 1H), 7.88 (d, J = 2.8 Hz, 1H), 7.76 (d,
J = 8.8 Hz, 1H), 7.23 (s, 1H), 7.20 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 4.40 (d, J = 15.2 Hz,
1H), 4.09 (s, 3H), 4.05 (s, 3H), 4.00 (s, 3H), 3.98–3.91 (m, 1H), 3.66 (d, J = 15.2 Hz, 1H),
3.41–3.37 (m, 1H), 3.10 (dd, J = 16.4 Hz, J = 3.2 Hz, 1H), 2.82 (dd, J = 16.4 Hz, J = 10.0
Hz, 1H), 2.35–2.30 (m, 1H), 2.15 (t, J = 10.4 Hz, 2H), 2.12–2.07 (m, 1H), 1.62–1.52 (m,
1H), 1.46–1.37 (m, 1H); ESI-HRMS ([M + H]+) calcd for C24H27NO4 394.2018, found
394.2016. For 19b: mp 228–230 °C; [α]23D= −81.5 ° (c 0.44, CHCl3); 1H NMR (400 MHz,
CDCl3): δ 7.86 (s, 1H), 7.85 (d, J = 2.4 Hz, 1H), 7.70 (d, J = 9.2 Hz, 1H), 7.19 (s, 1H), 7.15
(dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 4.30 (d, J = 15.2 Hz, 1H), 4.09 (s, 3H), 4.08 (m, 1H), 4.04
(s, 3H), 4.00 (s, 3H), 3.55 (d, J = 15.6 Hz, 1H), 3.26–3.23 (m, 1H), 3.05 (dd, J = 16.4 Hz, J =
3.2 Hz, 1H), 2.83 (dd, J = 16.4 Hz, J = 10.0 Hz, 1H), 2.43 (dd, J = 12.0 Hz, J = 1.6 Hz, 1H),
2.41–2.35 (m, 1H), 1.98–1.94 (m, 1H), 1.90–1.85 (m, 2H), 1.69–1.61 (m, 1H); ESI-HRMS
([M + H]+) calcd for C24H27NO4 394.2018, found 394.2022.
(14R/S,14aS)-11-Oxo-14-hydroxyl-cryptopleurine (20a/20b)
The preparation of the aldehyde was similar as for compounds 2a/2b. At −78 °C under N2,
to a solution of LiHMDS (1.5 mL, 1.50 mmol) in THF was added methyl propiolate (91μL,
1.10 mmol) and the reaction mixture was stirred for 1 h. Then the aldehyde (~ 1 mmol) in 10
mL of THF was added dropwise over 5 min. Stirring was continued for 2 h before sat.
NH4Cl was added. The mixture was warned to rt and CH2Cl2 was used for extraction. After
routine workup, the residue was dissolved in MeOH and subjected to catalytic
hydrogenation using Pd/C (100 mg) at 50 psi for 2 h. The catalyst was filtered off and the
solvent was evaporated under reduced pressure. Then the residue was dissolved in TFA/
CH2Cl2 and stirred for 1 h before Et3N (3 equiv.) and MeOH (15 mL) were added. The
resulting mixture was refluxed for 2 h. Finally, the mixture was chromatographed using
MeOH/CH2Cl2 to give an inseparable mixture of 20a and 20b (191 mg, 47%) as a white
solid. 1H NMR (400 MHz, CDCl3): δ 7.91–7.84 (m, 3H), 7.24–7.17 (m, 2H), 5.88 (d, J =
17.2 Hz, 0.58H), 5.72 (d, J = 17.2 Hz, 0.34H), 4.53–4.42 (d, J = 18.0 Hz, 1H), 4.22 (m, 0.77
H), 4.11 (s, 3H), 4.05 (s, 3H), 4.00 (s, 3H), 3.93–3.88 (m, 0.79H), 3.77–3.73 (m, 1H), 3.38
(dd, J = 16.0 Hz, J = 2.8 Hz, 1H), 2.95 (m, 1H), 2.84–2.71 (m, 1H), 2.61–2.48 (m, 1H),
2.27–2.20 (m, 1H), 2.10–2.02 (m, 1H); ESI-HRMS ([M + H]+) calcd for C24H25NO5
408.1811, found 408.1803.
(14S,14aS)-11-Oxo-14-hydroxycryptopleurine (21a) and (14R,14aS)-11-oxo-14-
hydroxycryptopleurine (21b)
The mixture of 20a/20b (84 mg, 0.21 mmol) was suspended in THF (20 mL), to which
borane-methyl sulfide (1.0 mL, 1.00 mmol) was added. The reaction mixture was stirred
overnight before MeOH (5 mL) was added and warmed to reflux for 0.5 h. The mixture was
chromatographed using MeOH/CH2Cl2 to afford 21a (14.4 mg) and 21b (18.8 mg) as white
solids. Yield: 41%. For 21a: mp 136–138 °C; [α]23D= −40.9° (c 0.23, CHCl3); 1H NMR
(400 MHz, CDCl3): δ 7.90–7.89 (m, 2H), 7.78 (d, J = 9.2 Hz, 1H), 7.29 (s, 1H), 7.19 (dd, J
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= 8.8 Hz, J = 2.4 Hz, 1H), 4.47 (d, J = 15.6 Hz, 1H), 4.10 (s, 3H), 4.05 (s, 3H), 4.01 (s, 3H),
3.91 (br s, 1H), 3.67 (d, J = 15.6 Hz, 1H), 3.53 (dd, J = 16.4 Hz, J = 10.4 Hz, 1H), 3.24–3.21
(m, 1H), 2.98 (dd, J = 16.8 Hz, J = 4.0 Hz, 1H), 2.61–2.57 (m, 2H), 2.34–2.28 (m, 1H),
2.10–2.03 (m, 2H), 1.69–1.66 (m, 1H); ESI-HRMS ([M + H]+) calcd for C24H27NO4
394.2018, found 394.2017. For 21b: mp 239 °C (dec.); [α]23D= −170.9° (c 0.11,
CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.90 (s, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.77 (d, J =
9.2 Hz, 1H), 7.31 (s, 1H), 7.19 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 4.47 (d, J = 15.6 Hz, 1H),
4.10 (s, 3H), 4.06 (s, 3H), 4.01 (s, 3H), 3.71–3.64 (m, 2H), 3.60 (dd, J = 16.4 Hz, J = 3.2 Hz,
1H), 3.22–3.19 (m, 1H), 2.96 (dd, J = 16.4 Hz, J = 9.2 Hz, 1H), 2.34–2.28 (m, 2H), 2.19–
2.16 (m, 1H), 1.89–1.81 (m, 2H), 1.50–1.44 (m, 1H); ESI-HRMS ([M + H]+) calcd for
C24H27NO4 394.2018, found 394.2013.
(R,E)-N-Boc-3-(4-ethoxy-4-oxobut-2-enyl)-6,7,10-trimethoxy-3,4-dihydrodibenzo
[f,h]isoquinoline (22)
To a solution of compound 10 (233 mg, 0.50 mmol) in CH2Cl2 (10 mL) was added
Ph3P=CH2CO2Et (348 mg, 1 mmol) in one portion. The reation mixture was stirred at 40 °C
for 5 h. After normal workup, the residue was chromatographed using EtOAc/hexane to give
238 mg of 22 as a light yellow foam in a yield of 89%. mp 173–175 °C; [α]23D= 146.9° (c
0.13, CHCl3); 1H NMR (400 MHz, CDCl3, peak broadened due to rotamers at r.t.): δ 7.93–
7.78 (m, 3H), 7.28–7.22 (m, 2H), 7.03–6.83 (m, 1H), 5.91–5.78 (d, J = 15.6 Hz, 1H), 5.41–
5.23 (m, 1H), 5.06–4.89 (m, 1H), 4.65–4.50 (d, J = 16.8 Hz, 1H), 4.16 (q, J = 7.2 Hz, 2H),
4.11 (s, 3H), 4.04 (s, 3H), 4.02 (s, 3H), 3.40–3.29 (dd, J = 16.0 Hz, J = 6.0 Hz, 1H), 3.09 (d,
J = 16.4 Hz, 1H), 2.57–2.50 (m, 1H), 2.34 (br s, 1H), 1.53 (s, 9H), 1.27 (t, J = 7.2 Hz, 3H);
ESI-HRMS ([M + H]+) calcd for C31H37NO7 536.2648, found 536.2652.
(12S/13S,12R/13R,14aS)-11-Oxo-12,13-dihydroxycryptopleurine (23a/23b)
To a solution of amide 22 (238 mg, 0.44 mmol) in 15 mL of acetone and H2O (8:1) was
sequentially added OsO4 (2.5wt% in t-BuOH, 0.05 mmol) and 4-methylmorpholine N-oxide
(155 mg, 1.32 mmol). The reaction mixture was stirred at 50 °C for 6 h before excess
Na2S2O3 was added to quench the reaction. The mixture was extracted with CH2Cl2,
washed with brine, and dried over Na2SO4. The solvent was then removed in vacuo, 10 mL
of TFA in CH2Cl2 (1:1) was added, and the mixture was stirred for 0.5 h. After that, the
solvent was evaporated and the trace of TFA was neutralized by Et3N. The residue was
stirred in 10 mL of MeOH and 0.2 mL of Et3N for 2 h. Chromatography using MeOH/
CH2Cl2 gave an inseparable mixture of 23a and 23b as a yellow solid (130 mg, yield: 67%
over three steps, in about 5:4 ratio as indicated by NMR). 1H NMR (400 MHz, CDCl3): δ
7.92–7.84 (m, 3H), 7.27–7.17 (m, 2H), 6.00 (d, J = 17.2 Hz, 0.43H), 5.54 (d, J = 18.0 Hz,
0.56H), 4.62 (d, J = 18.0 Hz, 0.65H), 4.45 (d, J = 17.2 Hz, 0.51H), 4.24 (m, 0.65H), 4.11 (s,
3H), 4.07 (s, 3H), 4.02 (m, 4H), 3.77 (m, 0.71H), 3.38 (dd, J = 16.0 Hz, J = 3.2 Hz, 1H),
2.97 (dd, J = 16.4 Hz, J = 10.8 Hz, 1H), 2.67–2.64 (m, 1H), 2.41–2.31 (m, 1H), 2.00 (m,
1H); ESI-HRMS ([M + H]+) calcd for C24H25NO6 424.1760, found 424.1757.
(12S,13S,14aS)-12,13-Dihydroxycryptopleurine (24a) and (12R,13R,14aS)-12,13-
dihydroxycryptopleurine (24b)
Similar procedure as for compounds 21a and 21b. For 24a: mp 225–227 °C; [α]23D=
−100.3° (c 0.10, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.90 (s, 1H), 7.88 (d, J = 2.4 Hz,
1H), 7.76 (d, J = 9.2 Hz, 1H), 7.23 (s, 1H), 7.20 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 4.48 (d, J =
15.6 Hz, 1H), 4.10 (s, 3H), 4.06 (s, 3H), 4.01 (s, 3H), 3.83–3.77 (m, 1H), 3.71–3.68 (m, 1H),
3.65–3.59 (m, 1H), 3.43 (dd, J = 11.2 Hz, J = 4.4 Hz, 1H), 3.16 (dd, J = 16.4 Hz, J = 3.2 Hz,
1H), 2.90 (dd, J = 16.4 Hz, J = 10.0 Hz, 1H), 2.57–2.52 (m, 1H), 2.38–2.33 (m, 1H), 2.30 (t,
J = 10.4 Hz, 1H), 1.64 (q, J = 12.0 Hz, 1H); ESI-HRMS ([M + H]+) calcd for C24H27NO5
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410.1967, found 410.1970. For 24b: mp 246–248 °C; [α]23D= −112.7° (c 0.15, CHCl3); 1H
NMR (400 MHz, CDCl3): δ 7.90 (s, 1H), 7.88 (d, J = 2.4 Hz, 1H), 7.76 (d, J = 9.2 Hz, 1H),
7.22 (s, 1H), 7.19 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 4.37 (d, J = 15.2 Hz, 1H), 4.10 (s, 3H),
4.08 (m, 1H), 4.06 (s, 3H), 4.00 (s, 3H), 3.83 (br s, 1H), 3.77 (d, J = 15.6 Hz, 1H), 3.11 (dd,
J = 12.0 Hz, J = 3.2 Hz, 1H), 3.04 (m, 1H), 2.93 (dd, J = 12.0 Hz, J = 1.6 Hz, 1H), 2.88–2.85
(m, 2H), 2.09–2.06 (m, 2H); ESI-HRMS ([M + H]+) calcd for C24H27NO5 410.1967, found
410.1978.
(13R,14aS)-13-Ethyl-13-hydroxycryptopleurine (25)
To a solution of compound 12 (14 mg, 0.036 mmol) in THF was added EtMgBr (0.10 mL,
0.10 mmol) under N2 at 0 °C. The resulting mixture was stirred for 1 h before sat. NH4Cl
was added to quench the reaction. CH2Cl2 was used for extraction. The organic layers were
combined and washed with aq. NaHCO3 and brine, and dried over Na2SO4. The solvent was
removed in vacuo and the residue was chromatographed using MeOH/CH2Cl2 to give 25
(7.8 mg, 51%) as a light yellow solid. mp 208–210 °C; [α]23D= −118.5° (c 0.11, CHCl3); 1H
NMR (400 MHz, CDCl3): δ 7.88 (s, 1H), 7.86 (d, J = 2.4 Hz, 1H), 7.78 (d, J = 8.8 Hz, 1H),
7.19 (s, 1H), 7.18 (dd, J = 8.8 Hz, J = 2.4 Hz, 1H), 4.46 (d, J = 15.2 Hz, 1H), 4.09 (s, 3H),
4.03 (m, 1H), 3.99 (s, 3H), 3.66 (d, J = 15.6 Hz, 1H), 3.12–3.08 (m, 1H), 3.01 (dd, J = 16.0
Hz, J = 2.4 Hz, 1H), 2.82 (dd, J = 16.0 Hz, J = 11.2 Hz, 1H), 2.75–2.69 (m, 2H), 1.96 (dt, J =
10.2 Hz, J = 2.8 Hz, 1H), 1.86 (dt, J = 11.2 Hz, J = 4.4 Hz, 1H), 1.72–1.68 (m, 1H), 1.59 (q,
J = 7.6 Hz, 2H), 1.55 (m, 1H), 1.01 (t, J = 7.6 Hz, 3H); ESI-HRMS ([M + H]+) calcd for
C26H31NO4 422.2331, found 422.2349.
(13S,14aS)-13-Methoxycryptopleurine (26a) and (13R,14aS)-13-methoxycryptopleurine
(26b)
To a solution of LiHMDS (0.30 mmol) in THF under Ar was added EtOAc (25 μl, 0.25
mmol) in 1 mL of THF at −78 °C, and the resulting mixture was stirred for 1 h before
compound 10 (93 mg, 0.20 mmol) in 1 mL of THF was added slowly. The reaction mixture
was stirred at −78 °C for about 2 h as indicated by TLC. Then sat. NH4Cl was added and the
mixture was extracted with CH2Cl2, dried over Na2SO4. After the Boc group was removed
with TFA, the residue was stirred in Et3N/MeOH for 2 h and the intermediate was purified
through a short column using MeOH/CH2Cl2 as elutant. The solvent was evaporated and the
residue was redissolved in THF, to which NaH (20 mg) was added. The reaction mixture
was stirred for 0.5 h followed by addition of Me2SO4 before the temperature was warmed to
50 °C. The reaction was quenched as monitored by TLC (about 1 h) and after normal
workup, the mixture was dried over Na2SO4. At last, the solvent was removed in vacuo and
the residue was redissolved in THF, to which BMS (0.2 mL, 0.20 mmol) was added. The
mixture was stirred overnight and MeOH was used to quench the reaction in reflux. The
mixture was purified using MeOH/CH2Cl2 as elutant to give 7.2 mg of 26a and 6.4 mg of
26b as light yellow solids in 17% yield over five steps. For 26a: mp 218–220 °C; [α]23D=
−83.8 ° (c 0.29, CHCl3); 1 H NMR (400 MHz, CDCl3): δ 7.91 (s, 1H), 7.89 (d, J = 2.4 Hz,
1H), 7.79 (d, J = 9.2 Hz, 1H), 7.26 (s, 1H), 7.19 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 4.49 (d, J =
15.6 Hz, 1H), 4.10 (s, 3H), 4.06 (s, 3H), 4.01 (s, 3H), 3.60 (d, J = 15.6 Hz, 1H), 3.44 (s, 3H),
3.39–3.30 (m, 2H), 3.14 (dd, J = 16.4 Hz, J = 3.2 Hz, 1H), 2.94 (dd, J = 16.0 Hz, J = 10.4
Hz, 1H), 2.47–2.31 (m, 3H), 2.21–2.17 (m, 1H), 1.76–1.66 (m, 1H), 1.54–1.46 (m, 1H);
ESI-HRMS ([M + H]+) calcd for C25H29NO4 408.2175, found 408.2178. For 26b: mp 115–
117 °C; [α]23D= −183.8° (c 0.08, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.91 (s, 1H), 7.89
(d, J = 2.4 Hz, 1H), 7.79 (d, J = 9.2 Hz, 1H), 7.24 (s, 1H), 7.19 (dd, J = 9.2 Hz, J = 2.4 Hz,
1H), 4.45 (d, J = 15.2 Hz, 1H), 4.10 (s, 3H), 4.06 (s, 3H), 4.01 (s, 3H), 3.72 (d, J = 16.0 Hz,
1H), 3.69 (m, 1H), 3.40 (s, 3H), 3.09–3.01 (m, 2H), 2.89–2.78 (m, 2H), 2.74–2.67 (m, 1H),
2.31–2.26 (m, 1H), 2.09–2.04 (m, 1H), 1.98–1.89 (m, 1H), 1.71–1.64 (m, 1H); ESI-HRMS
([M + H]+) calcd for C25H29NO4 408.2175, found 408.2169.
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ABBREVIATIONS
ATL adult T-cell leukemia




HTLV-1 human T-cell leukemia virus type 1
HUVEC human umbilical vein endothelial cell
NMM N-methylmorpholine
Py•SO3 sulfur trioxide pyridine complex
LiHMDS lithium bis(trimethylsilyl)amide (LiHMDS)
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Representatives of phenanthroindolizidines and phenanthroquinolizidines
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Inhibitory effect of selected compounds on CL1-5 NSCLC cell proliferation. Cell viability
was determined by SRB assay. *Compound 16 in Ref. 11. ** 8-membered E-ring analog.
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Morphological effect of 13b on A549 cells.
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(a) Inhibition of HSP90 and β-catenin by 13b through RT-PCR analysis. (b) Western blot
analysis of 13b in A549 cells for 48 h. Whole cell extracts were prepared and used for
immunoblot analysis using the indicated antibodies.
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Proposed pathways involved in 13b-induced cytotoxic effect in A549 cells modified from
the MetaCore databases.
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Reagents and conditions: (a) i) Py·SO3, DMSO, Et3N, CH2CI2; ii) LiHMDS, EtOAc, −78
°C, THF; iii) TFA, CH2CI2; iv) Et3N, MeOH, reflux, 57% over four steps (b) LiAIH4, THF,
70%
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Reagents and conditions: (a) i) TFA, CH2CI2; ii) 2-methylacrylic acid, EDC, HOBt, DMF,
83% over two steps (b) Grubb's 2nd generation catalyst, CH2CI2, 88% (c) LiAIH4, THF,
69% (d) HCI, THF, reflux, 68% (e) NaBH4, MeOH, r.t., 80%, 9a/9b = 5/3
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Reagents and conditions: (a) i) vinylmagnesium bromide, THF, 0 °C ii) Dess-Martin
reagent, CH2Cl2, 57% over two steps (b) i) TMSI, CH3CN, 0 °C; ii) Cs2CO3, MeOH, reflux,
63% over two steps (c) NaBH4, MeOH, 13a:13b= 3:7, 80% or L-selectride, THF, 0°C, 13a:
13b = 1:9, 90%
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Reagents and conditions: (a) Ph3P=CH2Br, n-BuLi, THF, 85% (b) i) TFA, CH2CI2; ii) 2-
methoxyacrylicacid, EDC, HOBt, DMF, 77% (c) Grubb's 2nd generation catalyst, CH2CI2,
reflux, 65% (d) LiAIH4, THF, 70% (e) HCI, THF, reflux, 80% (f) NaBH4, MeOH, 19a:19b
= 4:1,73% or L-selectride, THF, 0°C, 19a (80%), 19b (0%)
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Reagents and conditions: (a) i) Py·SO3, DMSO, Et3N, CH2CI2; ii) LiHMDS, methyl
propiolate, −78 °C, THF; iii) Pd/C, H2, MeOH; iv) TFA, CH2CI2; v) Et3N, MeOH, reflux,
47% over five steps (b) BMS, THF, 41%
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Reagents and conditions: (a) Ph3P=CH2CO2Et, THF, 89% (b) i) OSO4, NMO, Acetone/
H20=8/1, overnight; ii) TFA, CH2CI2; iii) TEA, MeOH, reflux, 67% over three steps (c)
BMS, THF, 37%
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Reagents and conditions: (a) EtMgBr, THF, 0 °C, 51% (b) i) LiHMDs, ethyl acetate, THF,
−78 °C; ii) TFA, CH2CI2; iii) MeOH, Et3N; iv) Me2SO4, NaH, THF; v) BMS, THF, 17%
over five steps
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Table 5
Inhibitory effects of 13b and R-cryptopleurine on human NSCLC cell lines
IC50 (nM)
Cell line 13b R-cryptopleurine S-oxa-cryptopleurine
CL1–0 58.4 ± 0.02 5 ± 0.02 -
CL1–5 8.7 ± 0.02 1.8 ± 0.01 -
A549 9 ± 0.02 1.9 ± 0.11 40 ± 6
PC9 8.2 ± 0.03 5.5 ± 0.03 -
PC9IR 43.2 ± 0.01 6.8 ± 0.01 -
MRC-5 98 ± 10 14 ± 2 252 ± 24
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Table 6




5.423E-07Down-regulation: HSP90, SAP18, CDK11, β-catenin, Casein kinase I, Skp2/TrCP/
FBXW, PKA-cat (cAMP-dependent), DYRK2
Cell adhesion plasma signaling Down-regulation: Fibronectin, PI3K cat. Class IA, XIAP, PLAU (UPA), FRS2, PI3Kreg. class IA, Collagen IV 8.889E-06
Transport clathrin-coated vesicle cycle Down-regulation: Myosin Vb, Rabaptin-5, Syntazin 7, PLEKHA8 (FAPP2),SNAP-25, Eps 15, VTI1B, EEA1, PECALM 2.284E-05
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